Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.

Klener P.

Int J Mol Sci. 2019 Sep 8;20(18). pii: E4417. doi: 10.3390/ijms20184417. Review.

2.

A three-pronged "Pitchfork" strategy enables an extensive description of the human membrane proteome and the identification of missing proteins.

Vit O, Harant K, Klener P, Man P, Petrak J.

J Proteomics. 2019 Jul 30;204:103411. doi: 10.1016/j.jprot.2019.103411. Epub 2019 Jun 6.

PMID:
31176011
3.

First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients.

Janikova A, Chloupkova R, Campr V, Klener P, Hamouzova J, Belada D, Prochazka V, Pytlik R, Pirnos J, Duras J, Mocikova H, Bortlicek Z, Kopalova N, Mayer J, Trneny M.

Ann Hematol. 2019 Aug;98(8):1961-1972. doi: 10.1007/s00277-019-03694-y. Epub 2019 May 8.

PMID:
31065733
4.

Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma.

Prukova D, Andera L, Nahacka Z, Karolova J, Svaton M, Klanova M, Havranek O, Soukup J, Svobodova K, Zemanova Z, Tuskova D, Pokorna E, Helman K, Forsterova K, Pacheco-Blanco M, Vockova P, Berkova A, Fronkova E, Trneny M, Klener P.

Clin Cancer Res. 2019 Jul 15;25(14):4455-4465. doi: 10.1158/1078-0432.CCR-18-3275. Epub 2019 Apr 19.

PMID:
31004002
5.

3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.

Jorda R, Havlíček L, Šturc A, Tušková D, Daumová L, Alam M, Škerlová J, Nekardová M, Peřina M, Pospíšil T, Široká J, Urbánek L, Pachl P, Řezáčová P, Strnad M, Klener P, Kryštof V.

J Med Chem. 2019 May 9;62(9):4606-4623. doi: 10.1021/acs.jmedchem.9b00189. Epub 2019 Apr 17.

PMID:
30943029
6.

Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation.

Klener P, Salek D, Pytlik R, Mocikova H, Forsterova K, Blahovcova P, Campr V, Prochazka V, Obr A, Jaksa R, Kuntscherova J, Boudová L, Kodet R, Janikova A, Trneny M.

Am J Hematol. 2019 Feb;94(2):E50-E53. doi: 10.1002/ajh.25362. Epub 2018 Dec 13. No abstract available.

PMID:
30474171
7.

Effective doxorubicin-based nano-therapeutics for simultaneous malignant lymphoma treatment and lymphoma growth imaging.

Etrych T, Daumová L, Pokorná E, Tušková D, Lidický O, Kolářová V, Pankrác J, Šefc L, Chytil P, Klener P.

J Control Release. 2018 Nov 10;289:44-55. doi: 10.1016/j.jconrel.2018.09.018. Epub 2018 Sep 22.

PMID:
30248447
8.

The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group.

Belada D, Prochazka V, Janikova A, Campr V, Blahovcova P, Pytlik R, Sykorova A, Klener P, Benesova K, Pirnos J, Duras J, Mocikova H, Trneny M.

Leuk Res. 2018 Oct;73:29-38. doi: 10.1016/j.leukres.2018.08.019. Epub 2018 Aug 31.

PMID:
30195062
9.

Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry.

Obr A, Prochazka V, Papajik T, Klener P Jr, Janikova A, Salek D, Belada D, Pytlík R, Sykorova A, Mocikova H, Simkovic M, Campr V, Dlouha J, Furst T, Trněný M.

Leuk Lymphoma. 2019 Mar;60(3):748-755. doi: 10.1080/10428194.2018.1508672. Epub 2018 Sep 6.

PMID:
30188225
10.

Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.

Klener P, Fronkova E, Kalinova M, Belada D, Forsterova K, Pytlik R, Blahovcova P, Simkovic M, Salek D, Mocikova H, Prochazka V, Janikova A, Vaskova M, Mejstrikova E, Kodet R, Trka J, Trneny M.

Hematol Oncol. 2018 Dec;36(5):773-778. doi: 10.1002/hon.2550. Epub 2018 Sep 13.

PMID:
30129045
11.

Cyclin D1 mRNA as a molecular marker for minimal residual disease monitoring in patients with mantle cell lymphoma.

Lokvenc M, Kalinova M, Forsterova K, Klener P, Trneny M, Fronkova E, Kodet R.

Ann Hematol. 2018 Mar;97(3):467-474. doi: 10.1007/s00277-017-3210-8. Epub 2017 Dec 22.

PMID:
29273915
12.

Anaplastic Large-Cell Lymphoma Associated with Breast Implants: A Case Report of a Transgender Female.

Patzelt M, Zarubova L, Klener P, Barta J, Benkova K, Brandejsova A, Trneny M, Gürlich R, Sukop A.

Aesthetic Plast Surg. 2018 Apr;42(2):451-455. doi: 10.1007/s00266-017-1012-y. Epub 2017 Nov 3.

PMID:
29101436
13.

Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.

Klener P, Fronkova E, Belada D, Forsterova K, Pytlik R, Kalinova M, Simkovic M, Salek D, Mocikova H, Prochazka V, Blahovcova P, Janikova A, Markova J, Obr A, Berkova A, Kubinyi J, Vaskova M, Mejstrikova E, Campr V, Jaksa R, Kodet R, Michalova K, Trka J, Trneny M.

Hematol Oncol. 2018 Feb;36(1):110-115. doi: 10.1002/hon.2483. Epub 2017 Oct 30.

PMID:
29083050
14.

Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era.

Klener P Jr, Etrych T, Klener P.

Curr Med Chem. 2019;26(6):1002-1018. doi: 10.2174/0929867324666171006144725. Review.

PMID:
28990505
15.

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.

Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, Lenz G.

Blood. 2017 Jul 20;130(3):310-322. doi: 10.1182/blood-2016-12-758599. Epub 2017 Feb 15.

PMID:
28202458
16.

Comparison of Plasma Osteopontin Levels between Patients with Borderline Ovarian Tumours and Serous Ovarian Carcinoma.

Živný JH, Leahomschi S, Klener P Jr, Živný J, Haluzík M, Cibula D.

Folia Biol (Praha). 2016;62(6):258-262.

17.

Hematopoiesis in patients with mature B-cell malignancies is deregulated even in patients with undetectable bone marrow involvement.

Maswabi BC, Molinsky J, Savvulidi F, Zikmund T, Prukova D, Tuskova D, Klanova M, Vockova P, Lateckova L, Sefc L, Zivny J, Trneny M, Klener P.

Haematologica. 2017 Apr;102(4):e152-e155. doi: 10.3324/haematol.2016.151571. Epub 2017 Jan 5. No abstract available.

18.

B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.

Dai B, Grau M, Juilland M, Klener P, Höring E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Jöhrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, Lenz G.

Blood. 2017 Jan 19;129(3):333-346. doi: 10.1182/blood-2016-05-718775. Epub 2016 Nov 18.

19.

Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia.

Vargova J, Vargova K, Dusilkova N, Kulvait V, Pospisil V, Zavadil J, Trneny M, Klener P, Stopka T.

Blood Cancer J. 2016 Sep 23;6(9):e475. doi: 10.1038/bcj.2016.80. No abstract available.

20.

[Staging and Treatment Response Evaluation in Malignant Lymphomas - Czech Lymphoma Study Group Recommendations According to Criteria Revised in 2014 (Lugano Classification)].

Sýkorová A, Pytlík R, Móciková H, Belada D, Benešová K, Papajík T, Janíková A, Šálek D, Procházka V, Vokurka S, Campr V, Klener P, Kubáčková K, Trněný M.

Klin Onkol. 2016;29(4):295-302. Czech.

PMID:
27534788
21.

Single-agent cytarabine is insufficient for the treatment of human mantle cell lymphoma in mouse xenograft model.

Klanova M, Soukup T, Molinsky J, Lateckova L, Vockova P, Alam M, Zivny J, Trneny M, Klener P.

Neoplasma. 2016;63(5):774-8. doi: 10.4149/neo_2016_515.

PMID:
27468882
22.

Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.

Klener P, Fronkova E, Berkova A, Jaksa R, Lhotska H, Forsterova K, Soukup J, Kulvait V, Vargova J, Fiser K, Prukova D, Alam M, Calvin Lenyeletse Maswabi B, Michalova K, Zemanova Z, Jancuskova T, Pekova S, Trneny M.

Int J Cancer. 2016 Nov 15;139(10):2252-60. doi: 10.1002/ijc.30263. Epub 2016 Aug 2.

23.

Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells.

Otáhal P, Průková D, Král V, Fabry M, Vočková P, Latečková L, Trněný M, Klener P.

Oncoimmunology. 2015 Dec 3;5(4):e1115940. eCollection 2016 Apr.

24.

Significantly higher numbers of proB cells in healthy Caucasians compared to Asians: Is there association with incidence of CLL?

Molinsky J, Maswabi B, Prukova D, Klanova M, Vockova P, Zikmund T, Savvulidi F, Alam M, Sefc L, Vokurka M, Obrtlikova P, Trneny M, Klener P Jr.

Blood Cells Mol Dis. 2016 Mar;57:118-9. doi: 10.1016/j.bcmd.2015.12.001. Epub 2015 Dec 2. No abstract available.

PMID:
26684742
25.

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.

Czuczman NM, Barth MJ, Gu J, Neppalli V, Mavis C, Frys SE, Hu Q, Liu S, Klener P, Vockova P, Czuczman MS, Hernandez-Ilizaliturri FJ.

Blood. 2016 Mar 3;127(9):1128-37. doi: 10.1182/blood-2015-04-640920. Epub 2015 Dec 16.

26.

Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates.

Lidický O, Janoušková O, Strohalm J, Alam M, Klener P, Etrych T.

Molecules. 2015 Nov 4;20(11):19849-64. doi: 10.3390/molecules201119664.

27.

[Mantle Cell Lymphoma -  Cutting edge Dia-gnostics and Treatment Approaches].

Klener P Jr, Trněný M.

Klin Onkol. 2015;28 Suppl 3:3S80-6. Review. Czech.

PMID:
26489506
28.

[Malignant Lymphomas - Past, Present and Future].

Trněný M, Klener P Jr, Pytlík R.

Klin Onkol. 2015;28 Suppl 3:3S55-63. Review. Czech.

PMID:
26489503
29.

Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.

Klanova M, Andera L, Brazina J, Svadlenka J, Benesova S, Soukup J, Prukova D, Vejmelkova D, Jaksa R, Helman K, Vockova P, Lateckova L, Molinsky J, Maswabi BC, Alam M, Kodet R, Pytlik R, Trneny M, Klener P.

Clin Cancer Res. 2016 Mar 1;22(5):1138-49. doi: 10.1158/1078-0432.CCR-15-1191. Epub 2015 Oct 14. Erratum in: Clin Cancer Res. 2016 Aug 1;22(15):3984.

30.

Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells.

Lorkova L, Scigelova M, Arrey TN, Vit O, Pospisilova J, Doktorova E, Klanova M, Alam M, Vockova P, Maswabi B, Klener P Jr, Petrak J.

PLoS One. 2015 Aug 18;10(8):e0135314. doi: 10.1371/journal.pone.0135314. eCollection 2015.

31.

Immunotherapy Approaches in Cancer Treatment.

Klener P Jr, Otáhal P, Lateckova L, Klener P.

Curr Pharm Biotechnol. 2015;16(9):771-81. Review.

PMID:
26087990
32.

The use of formalin-fixed, paraffin-embedded lymph node samples for the detection of minimal residual disease in mantle cell lymphoma.

Kalinova M, Fronkova E, Klener P, Forsterova K, Lokvenc M, Mejstrikova E, Belada D, Mocikova H, Trneny M, Kodet R, Trka J.

Br J Haematol. 2015 Apr;169(1):145-8. doi: 10.1111/bjh.13182. Epub 2014 Oct 14. No abstract available.

PMID:
25312883
33.

Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.

Klanova M, Lorkova L, Vit O, Maswabi B, Molinsky J, Pospisilova J, Vockova P, Mavis C, Lateckova L, Kulvait V, Vejmelkova D, Jaksa R, Hernandez F, Trneny M, Vokurka M, Petrak J, Klener P Jr.

Mol Cancer. 2014 Jun 27;13:159. doi: 10.1186/1476-4598-13-159.

34.

Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research.

Klanova M, Soukup T, Jaksa R, Molinsky J, Lateckova L, Maswabi BC, Prukova D, Brezinova J, Michalova K, Vockova P, Hernandez-Ilizaliturri F, Kulvait V, Zivny J, Vokurka M, Necas E, Trneny M, Klener P.

Lab Invest. 2014 Jul;94(7):806-17. doi: 10.1038/labinvest.2014.61. Epub 2014 May 26.

35.

Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.

Pytlík R, Belada D, Kubáčková K, Vášová I, Kozák T, Pirnos J, Bolomská I, Matuška M, Přibylová J, Campr V, Burešová L, Sýkorová A, Berková A, Klener P, Trněný M; Czech Lymphoma Study Group.

Leuk Lymphoma. 2015 Jan;56(1):57-64. doi: 10.3109/10428194.2014.904509. Epub 2014 Apr 29.

PMID:
24628294
36.

[Epigenetic cancer drugs and their role in anticancer therapy].

Klener P.

Vnitr Lek. 2013 Jun;59(6):463-5. Review. Czech.

PMID:
23808740
37.

Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database.

Salek D, Vesela P, Boudova L, Janikova A, Klener P, Vokurka S, Jankovska M, Pytlik R, Belada D, Pirnos J, Moulis M, Kodet R, Michal M, Janousova E, Muzik J, Mayer J, Trněný M.

Leuk Lymphoma. 2014 Apr;55(4):802-10. doi: 10.3109/10428194.2013.815349. Epub 2013 Aug 13.

PMID:
23772666
38.

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.

Cheah CY, George A, Giné E, Chiappella A, Kluin-Nelemans HC, Jurczak W, Krawczyk K, Mocikova H, Klener P, Salek D, Walewski J, Szymczyk M, Smolej L, Auer RL, Ritchie DS, Arcaini L, Williams ME, Dreyling M, Seymour JF; European Mantle Cell Lymphoma Network.

Ann Oncol. 2013 Aug;24(8):2119-23. doi: 10.1093/annonc/mdt139. Epub 2013 Apr 24.

PMID:
23616279
39.

In vivo growth of mantle cell lymphoma xenografts in immunodeficient mice is positively regulated by VEGF and associated with significant up-regulation of CD31/PECAM1.

Molinský J, Klánová M, Maswabi B, Soukup T, Trněný M, Nečas E, Živný J, Klener P.

Folia Biol (Praha). 2013;59(1):26-31.

40.

Resistance to TRAIL in mantle cell lymphoma cells is associated with the decreased expression of purine metabolism enzymes.

Pospisilova J, Vit O, Lorkova L, Klanova M, Zivny J, Klener P, Petrak J.

Int J Mol Med. 2013 May;31(5):1273-9. doi: 10.3892/ijmm.2013.1302. Epub 2013 Mar 13.

PMID:
23503700
41.

The plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms.

Beranova L, Pombinho AR, Spegarova J, Koc M, Klanova M, Molinsky J, Klener P, Bartunek P, Andera L.

Apoptosis. 2013 Jun;18(6):739-50. doi: 10.1007/s10495-013-0823-9.

PMID:
23456623
42.

[Targeted therapeutics and their role in the treatment of internal diseases].

Klener P.

Vnitr Lek. 2013 Jan;59(1):5-12. Czech.

PMID:
23427997
43.

Multi-level disruption of the extrinsic apoptotic pathway mediates resistance of leukemia cells to TNF-related apoptosis-inducing ligand (TRAIL).

Leahomschi S, Molinsky J, Klanova M, Andera L, Peterka M, Gasova Z, Klener P Sr, Trneny M, Necas E, Simonova T, Zivny J, Klener P Jr.

Neoplasma. 2013;60(2):223-31.

PMID:
23259793
44.

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network.

Dreyling M, Kluin-Nelemans HC, Beà S, Klapper W, Vogt N, Delfau-Larue MH, Hutter G, Cheah C, Chiappella A, Cortelazzo S, Pott C, Hess G, Visco C, Vitolo U, Klener P, Aurer I, Unterhalt M, Ribrag V, Hoster E, Hermine O; European MCL Network.

Leuk Lymphoma. 2013 Apr;54(4):699-707. doi: 10.3109/10428194.2012.733882. Epub 2012 Nov 21. Review.

PMID:
23020649
45.

Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

Molinsky J, Klanova M, Koc M, Beranova L, Andera L, Ludvikova Z, Bohmova M, Gasova Z, Strnad M, Ivanek R, Trneny M, Necas E, Zivny J, Klener P.

Leuk Lymphoma. 2013 Feb;54(2):372-80. doi: 10.3109/10428194.2012.710331. Epub 2012 Sep 8.

PMID:
22830613
46.

Molecularly-targeted and biological anti-cancer therapy.

Klener P Jr, Klener P.

Folia Biol (Praha). 2012;58(1):1-6. Review. No abstract available.

47.

N-phosphonocarbonylpyrrolidine derivatives of guanine: a new class of bi-substrate inhibitors of human purine nucleoside phosphorylase.

Rejman D, Panova N, Klener P, Maswabi B, Pohl R, Rosenberg I.

J Med Chem. 2012 Feb 23;55(4):1612-21. doi: 10.1021/jm201409u. Epub 2012 Feb 13.

PMID:
22264015
48.

Intrapleural bortezomib for the therapy of myelomatous pleural effusion: a case report.

Klanova M, Klener P, Trneny M, Straub J, Spicka I.

Case Reports Immunol. 2012;2012:978479. doi: 10.1155/2012/978479. Epub 2012 Oct 11.

49.

Reply to the letter to the editor by Guinn et al.

Karban J, Mocikova H, Pytlik R, Klener P, Trneny M.

Eur J Haematol. 2011 Nov;87(5):470. doi: 10.1111/j.1600-0609.2011.01699.x. Epub 2011 Oct 2. No abstract available.

PMID:
21883479
50.

[ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy].

Klener P, Klener P Jr.

Klin Onkol. 2010;23(4):203-9. Review. Czech.

PMID:
20806817

Supplemental Content

Loading ...
Support Center